<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727090</url>
  </required_header>
  <id_info>
    <org_study_id>1507-10</org_study_id>
    <nct_id>NCT00727090</nct_id>
  </id_info>
  <brief_title>Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients</brief_title>
  <official_title>Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conivaptan (Vaprisol) is FDA-Approved for the treatment of low serum sodium (hyponatremia),
      but there are few data in patients with neurologic disease. Very low serum sodium in patients
      with brain injury can be life-threatening and is associated with cerebral edema (swelling of
      brain tissue). This can be important in patients with brain hemorrhage, brain tumors, or
      stroke (cerebral infarction).

      This is a pilot study to test the hypothesis that conivaptan (Vaprisol) leads to a greater
      increase in sodium than usual care. Patients will be randomly assigned to usual care or the
      lower FDA-approved dose of conivaptan (Vaprisol). We will track the use of other
      interventions, such as the use of hypertonic saline (concentrated salt solution), diuretics
      and salt tablets. A blinded co-investigator will record neurologic examination results (NIH
      Stroke Scale and Glasgow Coma Scale).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment below goal.
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Sodium From Baseline to 6 Hours</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale</measure>
    <time_frame>48 hours</time_frame>
    <description>Standardized neurologic examination, ranging from 0 (best) to 42 (worst possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale</measure>
    <time_frame>48 hours</time_frame>
    <description>Standardized examination of mental status ranging from 3 (worst) to 15 (best possible)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Serum Sodium From Baseline to 12 Hours</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Sodium From Baseline to 18 Hours</measure>
    <time_frame>18 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Sodium From Baseline to 24 Hours</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Sodium From Baseline to 36 Hours</measure>
    <time_frame>36 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Sodium From Baseline to 48 Hours</measure>
    <time_frame>48 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conivaptan in addition to usual care at the discretion of the attending medical staff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care by the attending physician staff</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan</intervention_name>
    <description>Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vaprisol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe hyponatremia (Na &lt; 130 mmol/L) or

          -  symptomatic hyponatremia - Na &lt; 135 mmol/L for at least six hours with Glasgow Coma
             Scale &lt; 15

        Exclusion Criteria:

          -  Enrollment in the NMH high-risk spine protocol. These patients receive large amounts
             of fluids, have rapid changes in electrolytes, and are typically corrected in 48 hours

          -  Expected death from any cause

          -  Known sensitivity or allergy to conivaptan

          -  Renal failure (baseline creatinine &gt; 1.5 mg/dL)

          -  Clinical diagnosis of hypovolemia, or by central venous pressure (CVP) &lt; 5 mm Hg if a
             central venous catheter is in place

          -  Concomitant use of potent inhibitors of cytochrome P-450 isoenzyme 3A4 (e.g.,
             ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir). These agents are
             not commonly used in the Neuro-ICU

          -  Clinical diagnosis of liver failure or insufficiency

          -  Pregnancy (must be excluded before entry)

          -  Lack of informed consent from the patient or a legally authorized representative (LAR)

          -  Use of intra-arterial vasodilators (e.g. verapamil, nicardipine) within 24 hours (e.g.
             for vasospasm after SAH)

          -  Concern by the Neuro-ICU pharmacist of a drug-drug interaction that would meaningfully
             impact care (the Neuro-ICU pharmacist will review the medication regimen before
             recruitment)

          -  Patients with a diagnosis of diabetes insipidus or treated with vasopressin, since
             these patients are already treated for abnormal free water balance

          -  Patients with congestive heart failure, since this is an approved use of the drug
             (these patients are typically not cared for in the Neuro-ICU)

          -  Age&lt;18 years (these patients are not cared for at NMH)

          -  Inclusion declined by the attending physician or consulting study nephrologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M Naidech, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <results_first_submitted>July 21, 2010</results_first_submitted>
  <results_first_submitted_qc>September 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 27, 2010</results_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Andrew Naidech</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment: Conivaptan</title>
          <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
        </group>
        <group group_id="P2">
          <title>Usual Medical Care</title>
          <description>Usual care by the attending physician staff</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment: Conivaptan</title>
          <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
        </group>
        <group group_id="B2">
          <title>Usual Medical Care</title>
          <description>Usual care by the attending physician staff</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="22.0"/>
                    <measurement group_id="B2" value="67" spread="2"/>
                    <measurement group_id="B3" value="55" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Sodium From Baseline to 6 Hours</title>
        <time_frame>48 hours</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Conivaptan</title>
            <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Usual Medical Care</title>
            <description>Usual care by the attending physician staff</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to 6 Hours</title>
          <population>Intention to treat</population>
          <units>mMol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1.7"/>
                    <measurement group_id="O2" value="-0.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Change in serum sodium from baseline is not different between groups</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NIH Stroke Scale</title>
        <description>Standardized neurologic examination, ranging from 0 (best) to 42 (worst possible).</description>
        <time_frame>48 hours</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Sodium From Baseline to 12 Hours</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Conivaptan</title>
            <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Usual Medical Care</title>
            <description>Usual care by the attending physician staff</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to 12 Hours</title>
          <units>mMol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="4.0"/>
                    <measurement group_id="O2" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Sodium From Baseline to 18 Hours</title>
        <time_frame>18 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Conivaptan</title>
            <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Usual Medical Care</title>
            <description>Usual care by the attending physician staff</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to 18 Hours</title>
          <units>mMol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="4.0"/>
                    <measurement group_id="O2" value="1.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Sodium From Baseline to 24 Hours</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Conivaptan</title>
            <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Usual Medical Care</title>
            <description>Usual care by the attending physician staff</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to 24 Hours</title>
          <units>mMol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="3.2"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Sodium From Baseline to 36 Hours</title>
        <time_frame>36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Conivaptan</title>
            <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Usual Medical Care</title>
            <description>Usual care by the attending physician staff</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to 36 Hours</title>
          <units>mMol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5.6"/>
                    <measurement group_id="O2" value="-1.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Sodium From Baseline to 48 Hours</title>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Conivaptan</title>
            <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Usual Medical Care</title>
            <description>Usual care by the attending physician staff</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline to 48 Hours</title>
          <units>mMol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5"/>
                    <measurement group_id="O2" value="-0.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glasgow Coma Scale</title>
        <description>Standardized examination of mental status ranging from 3 (worst) to 15 (best possible)</description>
        <time_frame>48 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours after study start</time_frame>
      <desc>Hypovolemia, clincial diagnosis by intensivist or central venous pressure &lt; 5 mmg Hg; Hypotension, systolic BP &lt; 100 mm Hg or requiring new vasopressors; Rash at study drug infusion site; New core temperature at least 100.4F;</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment: Conivaptan</title>
          <description>Conivaptan per package labeling, 20 mg IV bolus followed by 20 mg IV infusion over 24 hours</description>
        </group>
        <group group_id="E2">
          <title>Usual Medical Care</title>
          <description>Usual care by the attending physician staff</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypovolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>New core temperature at least 100.4F</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew M Naidech</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-3592</phone>
      <email>a-naidech@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

